BioAge Labs, Inc. Balance Sheet
BIOA / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
BioAge Labs, Inc. had $295M in total assets and $272M in shareholders' equity as of FY2025. Total debt was $0 against $189M in cash, resulting in a $189M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $188.9M | $354.3M | $21.6M |
| Accounts Receivable | $769.0K | - | - |
| Current Assets | $286.8M | $357.1M | $25.3M |
| PP&E (Net) | $963.0K | $591.0K | $323.0K |
| Total Assets | $294.9M | $358.2M | $25.9M |
| Current Liabilities | $20.1M | $27.8M | $58.2M |
| Total Debt | $0 | $8.5M | $8.2M |
| Shareholders' Equity | $272.1M | $323.1M | -$173.4M |